Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 12/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.35 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620022 | 0.94 | XIAP (0.49) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4497034 | 0.92 | XIAP (0.48) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4485818 | 0.92 | XIAP (0.48) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4479568 | 0.90 | XIAP (0.51) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4499460 | 0.90 | XIAP (0.49) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4475754 | 0.88 | XIAP (0.44) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7246486 | 0.88 | XIAP (0.44) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4490420 | 0.88 | XIAP (0.48) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4493190 | 0.88 | XIAP (0.48) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4492156 | 0.87 | XIAP (0.44) | XIAPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | XIAP 559/4885PSEN1 7/4885PSEN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.